Stockreport

Galapagos Announces Encouraging New Results from Ongoing Phase 1/2 Study of CD19 CAR T-Cell Therapy, GLPG5101, in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma

Galapagos NV - American Depositary Shares  (GLPG) 
Last galapagos nv - american depositary shares earnings: 10/24 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: glpg.com/company-overview
PDF Data from the ongoing Phase 1/2 ATALANTA-1 study in a heavily pretreated R/R NHL patient population demonstrate high antitumor activity and an encouraging safety profile [Read more]